New FDA-Approved Treg Therapy to Reduce Chronic GVHD After Allogeneic HSCT

IF 23.9 1区医学 Q1 HEMATOLOGY

Blood Pub Date : 2026-10-02 DOI:10.1182/blood.2026035591

Nelson J. Chao

引用次数: 0

Abstract

The Precision-T phase 3 trial is the first randomized, multicenter demonstration that a centrally manufactured defined allograft is effective markedly reducing moderate-to-severe chronic GVHD and non-relapse mortality without loss of graft versus leukemia or graft failure and infection. The engineered graft appears to instruct immune reconstitution toward a regulated, tolerance-associated state, giving the product a mechanism for further studies. The question is how far we can further program it.

查看原文本刊更多论文

fda新批准Treg疗法减少同种异体造血干细胞移植后慢性移植物抗宿主病

Precision-T iii期试验是第一个随机、多中心的试验，该试验证明了中央制造的定义同种异体移植物可以有效地显著降低中重度慢性GVHD和非复发死亡率，而不会导致移植物与白血病或移植物衰竭和感染的损失。这种工程移植物似乎将免疫重建引导到一种受调节的、与耐受性相关的状态，这为该产品的进一步研究提供了一种机制。问题是我们能把它编程到什么程度。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood 医学-血液学

CiteScore

23.60

自引率

3.90%

发文量

955

审稿时长

1 months

期刊介绍： Blood, the official journal of the American Society of Hematology, published online and in print, provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. Primary research articles will be published under the following scientific categories: Clinical Trials and Observations; Gene Therapy; Hematopoiesis and Stem Cells; Immunobiology and Immunotherapy scope; Myeloid Neoplasia; Lymphoid Neoplasia; Phagocytes, Granulocytes and Myelopoiesis; Platelets and Thrombopoiesis; Red Cells, Iron and Erythropoiesis; Thrombosis and Hemostasis; Transfusion Medicine; Transplantation; and Vascular Biology. Papers can be listed under more than one category as appropriate.